Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Arnaud Leroy, Louise Carton, Harry Gomajee, Regis Bordet & Olivier Cottencin. (2017) Naltrexone in the treatment of binge eating disorder in a patient with severe alcohol use disorder: a case report. The American Journal of Drug and Alcohol Abuse 43:5, pages 618-620.
Read now
Read now
Laith N AL-Eitan, Saied A Jaradat, Steve YS Su, Guan K Tay & Gary K Hulse. (2012) Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent. Pharmacogenomics and Personalized Medicine 5, pages 99-111.
Read now
Read now
Michael Soyka, Henry R. Kranzler, Wim van den Brink, John Krystal, Hans-Jürgen Möller & Siegfried Kasper. (2011) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence. The World Journal of Biological Psychiatry 12:3, pages 160-187.
Read now
Read now
Marta Rodríguez-Arias, María Asunción Aguilar, Carmen Manzanedo & José Miñarro. (2010) Preclinical evidence of new opioid modulators for the treatment of addiction. Expert Opinion on Investigational Drugs 19:8, pages 977-994.
Read now
Read now
Colin N Haile & Thomas R Kosten. (2009) The Potential of Pharmacogenomics to Treat Drug Addiction. Pharmacogenomics 10:12, pages 1883-1886.
Read now
Read now
Colin N. Haile, Thomas R. Kosten & Therese A. Kosten. (2009) Pharmacogenetic Treatments for Drug Addiction: Cocaine, Amphetamine and Methamphetamine. The American Journal of Drug and Alcohol Abuse 35:3, pages 161-177.
Read now
Read now
Articles from other publishers (43)
Hesham Farouk Elarabi, Amanda J. Lee, Abdu Adem, Abuelgasim Elrasheed, John Marsden & Hamad Al Ghaferi. (2022) Lower buprenorphine elimination rate constant is associated with lower opioid use. Psychopharmacology 239:10, pages 3213-3221.
Crossref
Crossref
David P. Graham, Mark J. Harding & David A. Nielsen. 2022. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
437
490
.
Kenneth Blum, Abdalla Bowirrat, Eric R. Braverman, David Baron, Jean Lud Cadet, Shan Kazmi, Igor Elman, Panyotis K. Thanos, Rajendra D. Badgaiyan, William B. Downs, Debasis Bagchi, Luis Llanos-Gomez & Mark S. Gold. (2021) Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions. International Journal of Environmental Research and Public Health 18:21, pages 11529.
Crossref
Crossref
Arash Khanegheini, Masoumeh Khani, Shahram Zarrabian, Shahrokh Yousefzadeh-Chabok, Behrooz Khakpour Taleghani & Abbas Haghparast. (2021) Cannabidiol enhanced the development of sensitization to the expression of methamphetamine-induced conditioned place preference in male rats. Journal of Psychiatric Research 137, pages 260-265.
Crossref
Crossref
Vladislav Ruchkin, Roman Koposov, Lars Oreland, Britt af.Klinteberg & Elena L. Grigorenko. (2021) Dopamine-related receptors, substance dependence, behavioral problems and personality among juvenile delinquents. Personality and Individual Differences 169, pages 109849.
Crossref
Crossref
Luxi DuanXingyuan LiJunxia YanYingyi ChenRui LuoQiang ZhangXiangling FengXingli Li. (2020)
Association of
COMT
Gene Polymorphisms with Response to Methadone Maintenance Treatment Among Chinese Opioid-Dependent Patients
. Genetic Testing and Molecular Biomarkers 24:6, pages 364-369.
Crossref
Crossref
Hülya Türkan, Bensu Karahalil, Ela Kadıoğlu, Kenan Eren, Defne Tamar Gürol & Ali Esat Karakaya. (2019)
The association between the
OPRM1
A118G polymorphism and addiction in a Turkish population
. Archives of Industrial Hygiene and Toxicology 70:2, pages 97-103.
Crossref
Crossref
Joshua A. Bornhorst & Gwendolyn McMillin. 2019. Critical Issues in Alcohol and Drugs of Abuse Testing. Critical Issues in Alcohol and Drugs of Abuse Testing
43
57
.
Monica Bawor, Brittany B. Dennis, Charlie Tan, Guillaume Pare, Michael Varenbut, Jeff Daiter, Carolyn Plater, Andrew Worster, David C. Marsh, Meir Steiner, Rebecca Anglin, Dipika Desai, Lehana Thabane & Zainab Samaan. (2015) Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study. Addiction Science & Clinical Practice 10:1.
Crossref
Crossref
Fatemeh Sadeghzadeh, Vahab Babapour & Abbas Haghparast. (2015) Role of dopamine D1-like receptor within the nucleus accumbens in acute food deprivation- and drug priming-induced reinstatement of morphine seeking in rats. Behavioural Brain Research 287, pages 172-181.
Crossref
Crossref
Stéphane Mouly, Vanessa Bloch, Katell Peoc'h, Pascal Houze, Laurence Labat, Kamilia Ksouda, Guy Simoneau, Xavier Declèves, Jean Francois Bergmann, Jean‐Michel Scherrmann, Jean‐Louis Laplanche, Jean‐Pierre Lepine & Florence Vorspan. (2015) Methadone dose in heroin‐dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. British Journal of Clinical Pharmacology 79:6, pages 967-977.
Crossref
Crossref
David C. Perlman, Camila Gelpí-Acosta, Samuel R. Friedman, Ashly E. Jordan & Holly Hagan. (2015) Perceptions of genetic testing and genomic medicine among drug users. International Journal of Drug Policy 26:1, pages 100-106.
Crossref
Crossref
Kai Yue, Bao Miao Ma, Jun Qiao Xing, Xiao Kang Gong, Qin Ru, Lin Chen, Qi Xiong, Xiang Tian, Lu Liu, Yong Qing Gan, Dai Song Wang, Guo Zhang Jin & Chao Ying Li. (2014) <i>l</i>-Stepholidine, a Naturally Occurring Dopamine D1 Receptor Agonist and D2 Receptor Antagonist, Attenuates Methamphetamine Self-Administration in Rats. Advanced Materials Research 998-999, pages 169-172.
Crossref
Crossref
Kai Yue, Baomiao Ma, Lin Chen, Xiang Tian, Qin Ru, Yongping Gan, Daisong Wang, Guozhang Jin & Chaoying Li. (2014) L-Stepholidine, a naturally occurring dopamine D1 receptor agonist and D2 receptor antagonist, attenuates heroin self-administration and cue-induced reinstatement in rats. NeuroReport 25:1, pages 7-11.
Crossref
Crossref
C.A. Boateng, C.A. Schweppe & A.H. Newman. 2014. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering.
David A. Nielsen, Ellen M. Nielsen, Teja Dasari & Catherine J. Spellicy. 2014. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
589
624
.
David A. Nielsen, Sara C. Hamon & Thomas R. Kosten. (2013) The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial. Psychiatric Genetics 23:6, pages 225-232.
Crossref
Crossref
Jesus D. Mena, Ryan A. Selleck & Brian A. Baldo. (2013) Mu-Opioid Stimulation in Rat Prefrontal Cortex Engages Hypothalamic Orexin/Hypocretin-Containing Neurons, and Reveals Dissociable Roles of Nucleus Accumbens and Hypothalamus in Cortically Driven Feeding. The Journal of Neuroscience 33:47, pages 18540-18552.
Crossref
Crossref
Shane Darke. (2012) Pathways to heroin dependence: time to re‐appraise self‐medication. Addiction 108:4, pages 659-667.
Crossref
Crossref
Gabrielle L. McLemore, Tamorah Lewis, Catherine H. Jones & Estelle B. Gauda. (2013) Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome. Seminars in Fetal and Neonatal Medicine 18:1, pages 35-41.
Crossref
Crossref
Desirée González Callejas, Marisa Cañadas Garre, Margarita Aguilera, Enrique Jiménez Varo & Miguel A. Calleja Hernández. 2013. Omics for Personalized Medicine. Omics for Personalized Medicine
335
363
.
Laith N AL-Eitan, Saied A Jaradat, Gary K Hulse & Guan K Tay. (2012) Custom genotyping for substance addiction susceptibility genes in Jordanians of Arab descent. BMC Research Notes 5:1.
Crossref
Crossref
Thomas G. Brown & Marie Claude Ouimet. 2012. Alcohol‐Related Violence. Alcohol‐Related Violence
303
334
.
Richard L. Bell, Helen J.K. Sable, Giancarlo Colombo, Petri Hyytia, Zachary A. Rodd & Lawrence Lumeng. (2012) Animal models for medications development targeting alcohol abuse using selectively bred rat lines: Neurobiological and pharmacological validity. Pharmacology Biochemistry and Behavior 103:1, pages 119-155.
Crossref
Crossref
Sadie Geraghty & Carly Dixon. (2012) The use of naltrexone in pregnancy in opiate-dependent mothers. British Journal of Midwifery 20:7, pages 503-506.
Crossref
Crossref
Kai Yue, Baomiao Ma, Qin Ru, Lin Chen, Yongping Gan, Daisong Wang, Guozhang Jin & Chaoying Li. (2012) The dopamine receptor antagonist levo-tetrahydropalmatine attenuates heroin self-administration and heroin-induced reinstatement in rats. Pharmacology Biochemistry and Behavior 102:1, pages 1-5.
Crossref
Crossref
Joshua Bornhorst, Annjanette Stone, John Nelson & Kim Light. 2012. Pharmacogenomics of Alcohol and Drugs of Abuse. Pharmacogenomics of Alcohol and Drugs of Abuse
47
92
.
Erik W. Gunderson, Frances R. Levin, Margaret M. Rombone, Suzanne K. Vosburg & Herbert D. Kleber. (2011) Improving Temporal Efficiency of Outpatient Buprenorphine Induction. The American Journal on Addictions 20:5, pages 397-404.
Crossref
Crossref
Therese A. Kosten. (2011) Pharmacologically targeting the P2rx4 gene on maintenance and reinstatement of alcohol self-administration in rats. Pharmacology Biochemistry and Behavior 98:4, pages 533-538.
Crossref
Crossref
Francina Fonseca, Rafael de la Torre, Laura Díaz, Antonio Pastor, Elisabet Cuyàs, Nieves Pizarro, Olha Khymenets, Magí Farré & Marta Torrens. (2011) Contribution of Cytochrome P450 and ABCB1 Genetic Variability on Methadone Pharmacokinetics, Dose Requirements, and Response. PLoS ONE 6:5, pages e19527.
Crossref
Crossref
Linda Weiss, James E Egan, Michael Botsko, Julie Netherland, David A Fiellin & Ruth Finkelstein. (2011) The BHIVES Collaborative: Organization and Evaluation of a Multisite Demonstration of Integrated Buprenorphine/Naloxone and HIV Treatment. JAIDS Journal of Acquired Immune Deficiency Syndromes 56:Supplement 1, pages S7-S13.
Crossref
Crossref
M K Ho, D Goldman, A Heinz, J Kaprio, M J Kreek, M D Li, M R Munafò & R F Tyndale. (2010) Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical Pharmacology & Therapeutics 88:6, pages 779-791.
Crossref
Crossref
Francina Fonseca, Mònica Gratacòs, Geòrgia Escaramís, Rafael De Cid, Rocío Martín-Santos, Emilio Fernández-Espejo, Xavier Estivill & Marta Torrens. (2012) Response to Methadone Maintenance Treatment is Associated with the MYOCD and GRM6 Genes. Molecular Diagnosis & Therapy 14:3, pages 171-178.
Crossref
Crossref
Stephen D. Mague & Julie A. Blendy. (2010) OPRM1 SNP (A118G): Involvement in disease development, treatment response, and animal models. Drug and Alcohol Dependence 108:3, pages 172-182.
Crossref
Crossref
Frank Barile. 2010. Clinical Toxicology. Clinical Toxicology
150
163
.
Vadim Yuferov, Orna Levran, Dmitri Proudnikov, David A. Nielsen & Mary Jeanne Kreek. (2010) Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Annals of the New York Academy of Sciences 1187:1, pages 184-207.
Crossref
Crossref
Raymond Anton. (2021) Substance Abuse is a Disease of the Human Brain: Focus on Alcohol. Journal of Law, Medicine & Ethics 38:4, pages 735-744.
Crossref
Crossref
Bianca Jupp & Andrew J. Lawrence. (2010) New horizons for therapeutics in drug and alcohol abuse. Pharmacology & Therapeutics 125:1, pages 138-168.
Crossref
Crossref
Lara A. Ray & Kent E. Hutchison. 2011. Addiction Medicine. Addiction Medicine
1101
1114
.
Bankole A. Johnson & Gabrielle Marzani-Nissen. 2011. Addiction Medicine. Addiction Medicine
381
395
.
Lin-Lin Wang, Yong Li & Shu-Feng Zhou. (2009) Prediction of deleterious non-synonymous single nucleotide polymorphisms of genes related to ethanol-induced toxicity. Toxicology Letters 187:2, pages 99-114.
Crossref
Crossref
Emmanuel S. Onaivi. 2009. New Concepts of Psychostimulant Induced Neurotoxicity. New Concepts of Psychostimulant Induced Neurotoxicity
335
369
.
Chris D. MeletisNieske Zabriskie. (2008) Natural Approaches to Treating Addiction. Alternative and Complementary Therapies 14:6, pages 275-281.
Crossref
Crossref